Strong debut for Sage

Investors pile into Sage Therapeutics (NASDAQ:SAGE+65%) today. Shares are up $11.74 from the offer price of $18.00 on turnover of 2.6M.

The clinical-stage biotech focuses on rare disorders of the central nervous system (CNS). Its lead product is SAGE-547 for the treatment of super-refractory status epilepticus (SE), a medical emergency where the patient has a seizure lasting longer than five minutes. It is associated with a high incidence of morbidity and mortality. There are ~150,000 cases of SE in the U.S. each year resulting in 30,000 deaths. SAGE-547 is currently in Phase 1/2 development.

The IPO fills the company's coffers by ~$90M, increasing its cash position to ~$137M on a pro forma basis. It burned $17.5M in operations in 2013.


From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs